Are Postoperative Infections in the First 12 Months after Wide Resection and Megaprosthetic Replacement Associated with the Survival of Osteosarcoma Patients? Results of a Multicenter Study
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Definition of Early Periprosthetic Infection
2.3. Statistical Analysis
3. Results
3.1. Baseline Demographics
3.2. Prognostic Factors
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Jeys, L.; Kulkarni, A.; Grimer, R.; Carter, S.; Tillman, R.; Abudu, A. Endoprosthetic reconstruction for the treatment of musculoskeletal tumors of the appendicular skeleton and pelvis. J. Bone Joint Surg. Am. 2008, 90, 1265–1271. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Andreou, D.; Hardes, J.; Gosheger, G.; Henrichs, M.P.; Nottrott, M.; Streitburger, A. Interdisciplinary diagnostic and treatment of bone sarcomas of the extremities and trunk. Handchir. Mikrochir. Plast. Chir. 2015, 47, 90–99. [Google Scholar]
- Grimer, R.J.; Aydin, B.K.; Wafa, H.; Carter, S.R.; Jeys, L.; Abudu, A.; Parry, M. Very long-term outcomes after endoprosthetic replacement for malignant tumours of bone. Bone Joint J. 2016, 98-B, 857–864. [Google Scholar] [CrossRef] [PubMed]
- Jeys, L.M.; Grimer, R.J.; Carter, S.R.; Tillman, R.M.; Abudu, A. Post operative infection and increased survival in osteosarcoma patients: Are they associated? Ann. Surg. Oncol. 2007, 14, 2887–2895. [Google Scholar] [CrossRef] [PubMed]
- Kucerova, P.; Cervinkova, M. Spontaneous regression of tumour and the role of microbial infection–possibilities for cancer treatment. Anti-Cancer Drugs 2016, 27, 269. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ruckdeschel, J.C.; Codish, S.D.; Stranahan, A.; McKneally, M.F. Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N. Engl. J. Med. 1972, 287, 1013–1017. [Google Scholar] [CrossRef]
- Schantz, S.P.; Skolnik, E.M.; O’Neill, J.V. Improved survival associated with postoperative wound infection in laryngeal cancer: An analysis of its therapeutic implications. Otolaryngol.–Head Neck Surg. 1980, 88, 412–417. [Google Scholar] [CrossRef]
- Palmerini, E.; Meazza, C.; Tamburini, A.; Bisogno, G.; Ferraresi, V.; Asaftei, S.D.; Milano, G.M.; Coccoli, L.; Manzitti, C.; Luksch, R.; et al. Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2). Cancer 2022, 128, 1958–1966. [Google Scholar] [CrossRef]
- Lascelles, B.D.X.; Dernell, W.S.; Correa, M.T.; Lafferty, M.; Devitt, C.M.; Kuntz, C.A.; Straw, R.C.; Withrow, S.J. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Ann. Surg. Oncol. 2005, 12, 1073–1083. [Google Scholar] [CrossRef]
- Lee, J.A.; Kim, M.S.; Kim, D.H.; Lim, J.S.; Park, K.D.; Cho, W.H.; Song, W.S.; Lee, S.Y.; Jeon, D.G. Postoperative infection and survival in osteosarcoma patients. Ann. Surg. Oncol. 2009, 16, 147–151. [Google Scholar] [CrossRef]
- Chen, Y.U.; Xu, S.F.; Xu, M.; Yu, X.C. Postoperative infection and survival in osteosarcoma patients: Reconsideration of immunotherapy for osteosarcoma. Mol. Clin. Oncol. 2015, 3, 495–500. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Andreou, D.; Bielack, S.; Carrle, D.; Kevric, M.; Kotz, R.; Winkelmann, W.; Jundt, G.; Werner, M.; Fehlberg, S.; Kager, L.; et al. The influence of tumor-and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. Ann. Oncol. 2010, 22, 1228–1235. [Google Scholar] [CrossRef] [PubMed]
- Bielack, S.S.; Kempf-Bielack, B.; Delling, G.; Exner, G.U.; Flege, S.; Helmke, K.; Kotz, R.; Salzer-Kuntschik, M.; Werner, M.; Winkelmann, W.; et al. Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. J. Clin. Oncol. 2002, 20, 776–790. [Google Scholar] [CrossRef] [PubMed]
- Isakoff, M.S.; Bielack, S.S.; Meltzer, P.; Gorlick, R. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J. Clin. Oncol. 2015, 33, 3029–3035. [Google Scholar] [CrossRef] [Green Version]
- Luetke, A.; Meyers, P.A.; Lewis, I.; Juergens, H. Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat. Rev. 2014, 40, 523–532. [Google Scholar] [CrossRef]
- Bishop, M.W.; Janeway, K.A.; Gorlick, R. Future directions in the treatment of osteosarcoma. Curr. Opin. Pediatr. 2016, 28, 26–33. [Google Scholar] [CrossRef] [Green Version]
- Grimer, R.; Taminiau, A.; Cannon, S. Surgical outcomes in osteosarcoma. Bone Joint J. 2002, 84, 395–400. [Google Scholar] [CrossRef]
- Bielack, S.S.; Smeland, S.; Whelan, J.S.; Marina, N.; Jovic, G.; Hook, J.M.; Krailo, M.D.; Gebhardt, M.; Papai, Z.; Meyer, J.; et al. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. J. Clin. Oncol. 2015, 33, 2279–2287. [Google Scholar]
- Bielack, S.S.; Hecker-Nolting, S.; Blattmann, C.; Kager, L. Advances in the management of osteosarcoma. F1000Research 2016, 5, 2767. [Google Scholar] [CrossRef]
- Meyers, P.A.; Schwartz, C.L.; Krailo, M.D.; Healey, J.H.; Bernstein, M.L.; Betcher, D.; Ferguson, W.S.; Gebhardt, M.C.; Goorin, A.M.; Harris, M.; et al. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival—A report from the Children’s Oncology Group. J. Clin. Oncol. 2008, 26, 633–638. [Google Scholar] [CrossRef]
- Wedekind, M.F.; Wagner, L.M.; Cripe, T.P. Immunotherapy for osteosarcoma: Where do we go from here? Pediatr. Blood Cancer 2018, 65, e27227. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Muller, C.R.; Smeland, S.; Bauer, H.C.; Saeter, G.; Strander, H. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: Long term results of the Karolinska Hospital series. Acta Oncol. 2005, 44, 475–480. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kager, L.; Potschger, U.; Bielack, S. Review of mifamurtide in the treatment of patients with osteosarcoma. Ther. Clin. Risk Manag. 2010, 6, 279–286. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brard, C.; Piperno-Neumann, S.; Delaye, J.; Brugieres, L.; Hampson, L.V.; Le Teuff, G.; Le Deley, M.C.; Gaspar, N. Sarcome-13/OS2016 trial protocol: A multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma. BMJ Open 2019, 9, e025877. [Google Scholar] [CrossRef]
- Whelan, J.; Patterson, D.; Perisoglou, M.; Bielack, S.; Marina, N.; Smeland, S.; Bernstein, M. The role of interferons in the treatment of osteosarcoma. Pediatr. Blood Cancer 2010, 54, 350–354. [Google Scholar] [CrossRef]
- Strander, H.; Bauer, H.C.; Brosjo, O.; Fernberg, J.O.; Kreicbergs, A.; Nilsonne, U.; Silfversward, C.; Signomklao, T.; Soderlund, V. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol. 1995, 34, 877–880. [Google Scholar] [CrossRef] [Green Version]
- Jeys, L.M.; Grimer, R.J.; Carter, S.R.; Tillman, R.M. Periprosthetic infection in patients treated for an orthopaedic oncological condition. J. Bone Joint Surg. Am. 2005, 87, 842–849. [Google Scholar] [CrossRef]
- Theil, C.; Roder, J.; Gosheger, G.; Deventer, N.; Dieckmann, R.; Schorn, D.; Hardes, J.; Andreou, D. What is the Likelihood That Tumor Endoprostheses Will Experience a Second Complication After First Revision in Patients With Primary Malignant Bone Tumors And What Are Potential Risk Factors? Clin. Orthop. Relat. Res. 2019, 477, 2705–2714. [Google Scholar] [CrossRef]
- Greenland, S.; Mansournia, M.A.; Altman, D.G. Sparse data bias: A problem hiding in plain sight. BMJ 2016, 352, i1981. [Google Scholar] [CrossRef] [Green Version]
Variable |
All Patients
n (%) |
Infected Patients
n (%) |
Non-Infected
Patients n (%) | p-Value |
---|---|---|---|---|
Eligible patients | 437 (100) | 46 (11) | 391 (89) | |
Sex male female | 269 (62) 168 (38) | 29 (63) 17 (37) | 240 (61) 151 (39) | 0.874 |
Age ≤40 years old >40 years old | 386 (88) 51 (12) | 38 (83) 8 (17) | 348 (89) 43 (11) | 0.222 |
Tumor site femur tibia humerus others | 253 (58) 124 (28) 57 (13) 3 (1) | 29 (63) 16 (35) 1 (2) 0 (0) | 224 (57) 108 (28) 56 (14) 3 (1) | 0.200 |
Primary metastases no yes not available | 360 (82) 70 (16) 7 (2) | 41 (89) 4 (9) 1 (2) | 319 (82) 66 (17) 6 (2) | 0.326 |
Pathological fracture no yes not available | 380 (87) 51 (12) 6 (1) | 42 (91) 4 (9) 0 (0) | 338 (86) 47 (12) 6 (2) | 0.632 |
T stage T1 T2 T3 not available | 161 (37) 248 (57) 12 (3) 16 (3) | 21 (46) 22 (48) 3 (6) 0 (0) | 140 (36) 226 (58) 12 (3) 13 (3) | 0.196 |
Tumor response to neoadjuvant chemotherapy good (<10% vital tumor) poor (≥10% vital tumor) not available | 270 (62) 155 (35) 12 (3) | 29 (63) 15 (33) 2 (4) | 241 (62) 140 (36) 10 (4) | 0.745 |
Status at last follow-up no evidence of disease alive with disease died of disease died of other cause | 309 (71) 29 (6) 91 (21) 8 (2) | 35 (76) 4 (9) 7 (15) | 274 (70) 25 (6) 84 (22) 8 (2) | 0.521 |
Variable | n | % | 5-Year LR | p | 5-Year EFS | p | 5-year DSS | p | |||
---|---|---|---|---|---|---|---|---|---|---|---|
% | SE | % | SE | % | SE | ||||||
Age | |||||||||||
≤40 | 386 | 88 | 4 | 1.1 | 0.007 | 68 | 2.5 | 0.144 | 81 | 2.2 | 0.063 |
>40 | 51 | 12 | 12 | 4.7 | 58 | 7.0 | 70 | 6.8 | |||
Primary metastasis | |||||||||||
no | 360 | 84 | 5 | 1.2 | 0.977 | 72 | 2.5 | <0.0001 | 83 | 2.1 | 0.0001 |
yes | 70 | 16 | 6 | 3.5 | 38 | 6.2 | 58 | 6.7 | |||
Pathological fracture | |||||||||||
no | 380 | 88 | 5 | 1.1 | 0.035 | 69 | 2.5 | 0.003 | 83 | 2.1 | 0.001 |
yes | 51 | 12 | 11 | 4.7 | 51 | 7.4 | 59 | 7.6 | |||
T stage | |||||||||||
T1 | 161 | 38 | 2 | 1.2 | 0.049 | 77 | 3.4 | 0.002 | 83 | 3.2 | 0.074 |
T2 | 248 | 59 | 6 | 1.7 | 62 | 3.3 | 77 | 2.9 | |||
0.689 | 0.847 | 0.273 | |||||||||
T3 | 12 | 3 | 10 | 9.5 | 58 | 14.2 | 90 | 9.5 | |||
Histological response | |||||||||||
<10% vital tumor | 270 | 64 | 2 | 0.9 | <0.0001 | 79 | 2.6 | <0.0001 | 88 | 2.1 | <0.0001 |
≥10% vital tumor | 155 | 36 | 10 | 2.6 | 49 | 4.2 | 64 | 4.2 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Schwering, C.; Niethard, M.; Gosheger, G.; Smolle, M.A.; Traub, F.; Adam, S.; Henrichs, M.-P.; Dürr, H.R.; Hardes, J.; Tunn, P.-U.; et al. Are Postoperative Infections in the First 12 Months after Wide Resection and Megaprosthetic Replacement Associated with the Survival of Osteosarcoma Patients? Results of a Multicenter Study. Cancers 2022, 14, 2682. https://doi.org/10.3390/cancers14112682
Schwering C, Niethard M, Gosheger G, Smolle MA, Traub F, Adam S, Henrichs M-P, Dürr HR, Hardes J, Tunn P-U, et al. Are Postoperative Infections in the First 12 Months after Wide Resection and Megaprosthetic Replacement Associated with the Survival of Osteosarcoma Patients? Results of a Multicenter Study. Cancers. 2022; 14(11):2682. https://doi.org/10.3390/cancers14112682
Chicago/Turabian StyleSchwering, Christine, Maya Niethard, Georg Gosheger, Maria Anna Smolle, Frank Traub, Simon Adam, Marcel-Philipp Henrichs, Hans Roland Dürr, Jendrik Hardes, Per-Ulf Tunn, and et al. 2022. "Are Postoperative Infections in the First 12 Months after Wide Resection and Megaprosthetic Replacement Associated with the Survival of Osteosarcoma Patients? Results of a Multicenter Study" Cancers 14, no. 11: 2682. https://doi.org/10.3390/cancers14112682